Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689006 | 1.00 | MGLL (0.32) | MGLL | |
| SCHEMBL4309617 | 1.00 | MGLL (0.32) | MGLL | |
| SCHEMBL916283 | 0.86 | MGLL (0.33) | MGLL | |
| SCHEMBL978470 | 0.84 | MGLL (0.33) | MGLL | |
| SCHEMBL612317 | 0.84 | MGLL (0.33) | MGLL | |
| SCHEMBL916334 | 0.83 | MGLL (0.32) | MGLL | |
| SCHEMBL15991954 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL2974670 | 0.82 | MMP1 (0.39) | MGLL | |
| SCHEMBL915272 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL15992178 | 0.82 | PSMB8 (0.32) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434198-B2 | Compounds and methods for the treatment of neurodegenerative diseases | Resilio Therapeutics, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210206713-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Resilio Therapeutics, LLC | 2021-07-08 | — | — | US | disclosed |
| US-10464883-B2 | Compounds and methods for the treatment of neurodegenerative diseases | Resilio Therapeutics, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190270698-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Resilio Therapeutics, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20190270698-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Resilio Therapeutics, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20180118661-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Resilio Therapeutics, LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118661-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Resilio Therapeutics, LLC | 2018-05-03 | — | — | US | disclosed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-7531572-B2 | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use | XENOPORT, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-06-26 | — | — | US | disclosed |
| EP-1919859-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | Xenoport, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008013860-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007002013-A2 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | MGLL 656/4885 |
| US-20210206713-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OTC, OAT, ODC1 | MGLL 2515/4885 |
| US-20190270698-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OTC, OAT, ODC1 | MGLL 2515/4885 |
| US-20180118661-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OTC, OAT, CHAT | MGLL 2388/4885 |
| US-20080051458-A1 | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | ASNS, ASPH, DNPEP | MGLL 577/4885 |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | ACMSD, APEH, CPS1 | MGLL 906/4885 |
| US-11434198-B2 | Compounds and methods for the treatment of neurodegenerative diseases | OTC, OAT, ODC1 | MGLL 2515/4885 |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | MGLL 906/4885 |
| US-10464883-B2 | Compounds and methods for the treatment of neurodegenerative diseases | OTC, OAT, CHAT | MGLL 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.